Pathology of congenital Zika syndrome in Brazil: a case series

Viral antigens were localised to glial cells and neurons and associated with microcalcifications in all three fatal cases with microcephaly. Antigens were also seen in chorionic villi of one of the first trimester placentas. Tissues from all five cases were positive for Zika virus RNA by RT-PCR, and sequence analyses showed highest identities with Zika virus strains isolated from Brazil during 2015.

These findings provide strong evidence of a link between Zika virus infection and different congenital central nervous system malformations, including microcephaly as well as arthrogryposis and spontaneous abortions.

Read more

Congenital Zika virus syndrome in Brazil: a case series of the first 1501 livebirths with complete investigation

Zika virus congenital syndrome is a new teratogenic disease. Because many definite or probable cases present normal head circumference values and their mothers do not report having a rash, screening criteria must be revised in order to detect all affected newborn babies.

Read more

Vaccine protection against Zika virus from Brazil

Here we show that a single immunization of a plasmid DNA vaccine or a purified inactivated virus vaccine provides complete protection in susceptible mice against challenge with a ZIKV outbreak  strain from northeast Brazil. This ZIKV strain has recently been shown to cross the placenta and to induce fetal microcephaly and other congenital malformations in mice. We produced  DNA vaccines expressing full-length ZIKV pre-membrane and envelope (prM-Env) as well as a series of deletion mutants. The full-length prM-Env DNA vaccine, but not the deletion mutants, afforded complete protection against ZIKV as measured by absence of detectable viremia following challenge, and protective efficacy correlated with Env-specific antibody titers. Adoptive transfer of purified IgG from vaccinated mice conferred passive protection, and CD4 and CD8 T lymphocyte depletion in vaccinated mice did not abrogate protective efficacy. These data demonstrate that protection against ZIKVchallenge can be achieved by single-shot subunit and inactivated virus vaccines in mice and that Env-specific antibody titers represent key immunologic correlates of protection. Our findings suggest that the development of a ZIKV vaccine for humans will likely be readily achievable.

Study: Zika virus infections last longer during pregnancy

University of Wisconsin-Madison researchers studying monkeys have shown that one infection with Zika virus protects against future infection, though pregnancy may drastically prolong the time the virus stays in the body.

The researchers, led by UW-Madison pathology Professor David O’Connor, published a study today (June 28, 2016) in the journal Nature Communications describing their work establishing rhesus macaque monkeys at the Wisconsin National Primate Research Center as a model for studying the way Zika virus infections may progress in people.

The team of UW and Duke University scientists — which includes specialists in emergent and insect-borne diseases, genetics and immunology, pediatrics and pregnancy — have been working with infected monkeys for months.

“What we’ve shown in the monkey model matches a lot of what people have observed in epidemiological studies of humans,” says Emma Mohr, a pediatric infectious disease fellow at UW-Madison and first author on the study with Matthew Aliota and Dawn Dudley, research scientists in UW-Madison’s schools of Veterinary Medicine and Medicine and Public Health, respectively.

Read more

Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus

Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive antibody-dependent enhancement (ADE) of ZIKV infection. Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed that most antibodies that reacted to DENV envelope protein also reacted to ZIKV. Antibodies to linear epitopes, including the immunodominant fusion-loop epitope, were able to bind ZIKV but were unable to neutralize the virus and instead promoted ADE. Our data indicate that immunity to DENV might drive greater ZIKV replication and have clear implications for disease pathogenesis and future vaccine programs for ZIKV and DENV.

Read more

Zika Virus in the Human Placenta and Developing Brain: Cell Tropism and Drug Inhibition

Here, we identify the placental and brain cell populations most susceptible to ZIKV infection, provide evidence for a mechanism of viral entry, and show that a commonly used antibiotic protects cultured brain cells by inhibiting viral proliferation. In the early gestation placenta, the virus readily infected trophoblast subpopulations that are in direct contact with maternal blood and uterine cells, suggesting routes of ZIKV transmission to the embryo and fetus. In the brain, ZIKV preferentially infected neural stem cells, astrocytes, and microglia, whereas neurons were less susceptible to infection. These findings suggest mechanisms for microcephaly and other pathologic features of infants with congenital ZIKV infection that are not explained by neural stem cell infection alone, such as calcifications in the cortical plate and brain abnormalities caused by third trimester infection. Blocking a putative viral entry receptor, AXL, which is highly enriched in the infected placenta and brain cell types, reduced ZIKV infection of astrocytes in vitro. In a glial cell line, the macrolide antibiotic, azithromycin, inhibited viral proliferation and viral-induced cytopathic effects at clinically relevant concentrations. Our characterization of infection in primary human tissues clarifies the pathogenesis of congenital ZIKV infection and provides critical context for interpreting results from model systems. Further work on azithromycin and related compounds may yield additional therapeutic strategies to safely alleviate or prevent the most severe consequences of the epidemic.

Read more

Identification of Zika Virus and Dengue Virus Dependency Factors using Functional Genomics

The flaviviruses dengue virus (DENV) and Zika virus (ZIKV) are severe health threats with rapidly expanding ranges. To identify the host cell dependencies of DENV and ZIKV, we completed orthologous functional genomic screens using RNAi and CRISPR/Cas9 approaches. The screens recovered the ZIKV entry factor AXL as well as multiple host factors involved in endocytosis (RAB5C and RABGEF), heparin sulfation (NDST1 and EXT1), and transmembrane protein processing and maturation, including the endoplasmic reticulum membrane complex (EMC). We find that both flaviviruses require the EMC for their early stages of infection. Together, these studies generate a high-confidence, systems-wide view of human-flavivirus interactions and provide insights into the role of the EMC in flavivirus replication.

Figure thumbnail fx1

Read more

Scientists use CRISPR to discover Zika and dengue weaknesses

Scientists from Washington have discovered human proteins that Zika virus needs for replication by performing the first screen using gene editing tool CRISPR/Cas9, an advance that may help fight Zika, dengue and other emerging viral infections.

Using the RNAi and CRISPR/Cas9 screening technologies they had developed for dengue and influenza, researchers in the Brass lab began by knocking out or depleting each protein in the human genome one at a time, then seeing how Zika or dengue virus grew when that human protein was gone.

Read more

Uveitis Associated with Zika Virus Infection

 We report on a man in his early 40s who had an unremarkable medical history and a 2-day history of a rash and bilateral ocular hyperemia. ZIKV infection was diagnosed by means of a positive real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay of a serum specimen. A peripheral-blood sample was also positive for anti-ZIKV IgM antibodies detected by means of an in-house enzyme-linked immunosorbent assay and a plaque-reduction neutralization test (titer, 1:5000).We suspect that some persons with a diagnosis of ZIKV-related conjunctivitis may have intraocular inflammation. Uveitis may be a potential manifestation of ZIKV infection.

Read more

Scientists announce important Zika milestone: First vaccine ready for human trials

Pennsylvania vaccine maker Inovio Pharmaceuticals and South Korea’s GeneOne Life Sciences said Monday that they had received approval from U.S. regulators to start testing a DNA vaccine, known as GLS-5700, on humans. The early stage study will include 40 healthy subjects. It is designed to primarily assess the safety of the vaccine but will also measure the immune response generated by the injection. Zika, part of the flavivirus family of viruses that includes West Nile, dengue and yellow fever, is believed to be responsible for causing thousands of babies to be born with shrunken heads in Brazil and elsewhere. The Centers for Disease Control and Prevention recently detailed the cases of six babies born with the condition in the United States.

Read more